New combination therapy for Plavix draws keen attention

Published: 2011-01-07 07:00:00

Updated: 2011-01-07 07:00:00

Domestic pharmaceutical firms, Chong Kun Dang Pharmaceutical and Hanmi Pharmaceutical, have paid their keen attention to the ongoing regulatory screening for the new combination drug for Sanofi-Aventis’s Plavix.

Sources say Sanofi-Aventis submitted to the Korea Food and Drug Administration the...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK